For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

PPAR agonists, antigen-specific immune tolerance therapies and IBAT inhibitors lead the PBC pipeline as companies target patients with an inadequate response to UDCA.Dublin, Oct. (GLOBE NEWSWIRE) -- ...

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

The European Commission has granted conditional approval for Ipsen's IQIRVO (elafibranor) for the treatment of primary biliary cholangitis in adults, marking the first new therapy for this condition ...

The authors of this review assess the role of endoscopic retrograde cholangiopancreatography (ERCP) and emerging endoscopic techniques in the diagnosis, treatment, and management of primary sclerosing ...

AMSTERDAM — Patients with an incomplete response to first-line therapy for primary biliary cholangitis are significantly more likely to achieve a complete biochemical response with bezafibrate ...

Primary biliary cholangitis is a rare autoimmune disease that affects the liver and can progress to cirrhosis. It occurs when the immune system attacks the small bile ducts within the liver. As a ...

Primary Biliary Cholangitis: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty Primary biliary cholangitis (PBC) is a chronic liver disease that gradually damages the bile ducts ...

WASHINGTON, DC — Measures of liver stiffness remained stable or improved in patients with primary biliary cholangitis (PBC) after 36 months of treatment with seladelpar (Livdelzi) based on new data ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC). Iqirvo ...

In other drug development news, pharmaceutical company Cosmo said its placebo-controlled phase II trial of rifamycin 1% ...